Rheonix to Advance Automated Diagnostic Testing Technology through Strategic
Development agreement with Life Technologies addresses needs in clinical
diagnostics and food safety markets
ITHACA, N.Y. -- July 31, 2013
Rheonix, Inc., a developer of fully automated molecular testing solutions, and
Life Technologies Corp. (NASDAQ: LIFE), a global leader in the life sciences
tools and diagnostic markets, have entered into a joint development agreement
to introduce a molecular testing platform for their Applied Markets business.
Technology developed by Rheonix for the molecular diagnostics market,
including the Rheonix CARD^®, a disposable cartridge the size of a credit card
that can run multiple samples simultaneously without user intervention, will
be supplied by Rheonix to Life Technologies for marketing, sales and
distribution. The partnership will significantly shorten the time necessary
for Rheonix to enter the clinical market with its sample-to-result molecular
The instrument and consumable cartridges are components of a molecular
detection system specifically designed for the food testing market that will
enable laboratories to detect disease-causing organisms, including serotype
identification, in a fully automated and highly efficient manner. The new
platform is targeted for initial introduction in 2014.
“We are excited to work with the Applied Markets group based on their history
as an innovative, high-growth unit within Life Technologies,” said Tony
Eisenhut, president of Rheonix. “This partnership will bring us closer to our
goal of ensuring a safer food supply both domestically and around the globe.”
The companies entered into the joint development agreement after a robust
search and evaluation process by Life Technologies. Life Technologies selected
Rheonix to streamline laboratory workflow and provide greater breadth of
information per sample and offer a low cost of acquisition and operation.
For the clinical market, the walk-away Rheonix platform is fully automated and
addresses the most difficult challenges facing the health care industry today,
including workforce shortages, limited access to advanced molecular testing
and escalating costs. Once a raw sample is placed on the Rheonix CARD, the
automated platform runs with no user intervention through the process of
sample extraction, DNA purification, amplification and detection. This
eliminates the need for multiple pieces of existing equipment, helping make
the testing process quicker, more efficient, less expensive and less likely to
result in human error.
“This partnership is a great example of combining the consumable innovation of
Rheonix with the molecular testing menu and hardware expertise of Life
Technologies,” said Eisenhut. “The fact that Life Technologies chose Rheonix
validates the work we have done over the past decade to bring a molecular
diagnostic platform forward that will help the industry address some of the
major challenges in health care.”
Rheonix Inc. is committed to improving standards of care by making molecular
diagnostics available to more people, in more places, more often. Rheonix,
through experienced leadership and creative vision, has developed the
EncompassMDx™ platform, a highly customizable technology with unmatched
versatility and affordability. The platform performs fully automated, complex
molecular assays in an easy-to-use and economical format on the Rheonix CARD^®
cartridge. With both the Rheonix CARD and EncompassMDx family of products,
Rheonix is well-positioned to penetrate key molecular diagnostic market
sectors, from reference labs through point of care and everywhere in between.
For more information, visit www.rheonix.com.
Pinckney Hugo Group
Christopher Powers, 315-478-6700
Press spacebar to pause and continue. Press esc to stop.